Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity

American Journal of Physiology - Cell Physiology

Volumn 294, Issue 6, 2008, Pages

  Khan, Shaukat A ^a,b   Nelson, Matthew S ^a   Pan, Chendong ^a   Gaffney, Patrick M ^b   Gupta, Pankaj ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

Bone morphogenetic proteins; Glycosaminoglycans; Mucopolysaccharidosis I; Osteosarcoma; Stem cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; RNA; SMAD1 PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; CHORDIN; GLYCOPROTEIN; ID1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; SMAD1 PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; HURLER SYNDROME; MUCOPOLYSACCHARIDOSIS; MULTIPOTENT STEM CELL; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; GLYCOPROTEINS; HEPARIN; HEPARITIN SULFATE; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCOPOLYSACCHARIDOSIS I; MULTIPOTENT STEM CELLS; OSTEOSARCOMA; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; TIME FACTORS;

EID: 47249129552     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00346.2007     Document Type: Article

References (44)

1. Chang Z, Meyer K, Rapraeger AC, Friedl A. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 14: 137-144, 2000.
2. Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Biophys Acta 1333: F105-F150, 1997.
3. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 2189-2199, 2005.
4. Fisher MC, Li Y, Seghatoleslami MR, Dealy CN, Kosher RA. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation. Matrix Biol 25: 27-39, 2006.
5. Foletta VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG, Shannon M, He W, Das S, Massague J, Bernard O. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 162: 1089-1098, 2003.
6. Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 108: 175-180, 2001.
7. Fuchs O, Simakova O, Klener P, Cmejlova J, Zivny J, Zavadil J, Stopka T. Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4. Blood Cells Mol Dis 28: 221-233, 2002.
8. Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung C, Helman LJ, Picci P, Carinci P. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 20: 143-147, 2002.
9. Grisaru S, Cano-Gauci D, Tee J, Filmus J, Rosenblum ND. Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 231: 31-46, 2001.
10. Hu MC, Wasserman D, Hartwig S, Rosenblum ND. p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1. J Biol Chem 279: 12051-12059, 2004.
11. Irie A, Habuchi H, Kimata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 308: 858-865, 2003.
12. Jasuja R, Allen BL, Pappano WN, Rapraeger AC, Greenspan DS. Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin. J Biol Chem 279: 51289-51297, 2004.
13. Jeffery TK, Upton PD, Trembath RC, Morrell NW. BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. Am J Physiol Lung Cell Mol Physiol 288: L370-L378, 2005.
14. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 282: 1080-1086, 2007.
15. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 273: 21145-21152, 1998.
16. Khan SA, Park SW, Huq M, Wei LN. Protein kinase C-mediated phosphorylation of orphan nuclear receptor TR2: effects on receptor stability and activity. Proteomics 5: 3885-3894, 2005.
17. Khan SA, Park SW, Huq MD, Wei LN. Ligand-independent orphan receptor TR2 activation by phosphorylation at the DNA-binding domain. Proteomics 6: 123-130, 2006.
18. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60: 2840-2844, 2000.
19. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ, Morton RA. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23: 7651-7659, 2004.
20. Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275: 17647-17652, 2000.
21. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277: 4883-4891, 2002.
22. Krufka A, Guimond S, Rapraeger AC. Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation. Biochemistry 35: 11131-11141, 1996.
23. Machado RD, Rudarakanchana N, Atkinson C, Flanagan JA, Harrison R, Morrell NW, Trembath RC. Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 12: 3277-3286, 2003.
24. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23: 9326-9335, 2004.
25. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187: 265-276, 2001.
26. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW and Vogelstein B. New York: McGraw-Hill, 2001, p. 3421-3452.
27. Ohkawara B, Iemura S, ten Dijke P, Ueno N. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 12: 205-209, 2002.
28. Paine-Saunders S, Viviano BL, Economides AN, Saunders S. Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. J Biol Chem 277: 2089-2096, 2002.
29. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 225: 179-187, 2000.
30. Pan C, Nelson MS, Reyes M, Koodie L, Brazil JJ, Stephenson EJ, Zhao RC, Peters C, Selleck SB, Stringer SE, Gupta P. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biological activity of FGF-2 on human multipotent progenitor cells. Blood 106: 1956-1964, 2005.
31. Petryk A, Shimmi O, Jia X, Carlson AE, Tervonen L, Jarcho MP, O'Connor MB, Gopalakrishnan R. Twisted gastrulation and chordin inhibit differentiation and mineralization in MC3T3-E1 osteoblast-like cells. Bone 36: 617-626, 2005.
32. Rajan P, Panchision DM, Newell LF, McKay RD. BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol 161: 911-921, 2003.
33. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98: 2615-2625, 2001.
34. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237: 295-302, 1996.
35. Russell C, Hendson G, Jevon G, Matlock T, Yu J, Aklujkar M, Ng KY, Clarke LA. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 53: 349-361, 1998.
36. Shoji M, Tanabe N, Mitsui N, Tanaka H, Suzuki N, Takeichi O, Sugaya A, Maeno M. Lipopolysaccharide stimulates the production of prostaglandin E2 and the receptor Ep4 in osteoblasts. Life Sci 78: 2012-2018, 2006.
37. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A, Kamijo R. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278: 43229-43235, 2003.
38. Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet 4: 763-773, 2003.
39. Wei LN, Hu X, Chinpaisal C. Constitutive activation of retinoic acid receptor beta2 promoter by orphan nuclear receptor TR2. J Biol Chem 275: 11907-11914, 2000.
40. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 25: 2666-2673, 2006.
41. Whitley CB, McIvor RS, Aronovich EL, Berry SA, Blazar BR, Burger SR, Kersey JH, King RA, Faras AJ, Latchaw RE, McCullough J, Pan D, Ramsay NK, Stroncek DF. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther 7: 537-549, 1996.
42. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5: 2139-2148, 2006.
43. Yu PB, Beppu H, Kawai N, Li E, Bloch KD. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem 280: 24443-24450, 2005.
44. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281: 23246-23253, 2006.